Yacobus Christian Prasetyo
Department Of Pharmacology, Faculty Of Medicine, Universitas Kristen Duta Wacana, Yogyakarta

Published : 7 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search
Journal : Indonesian Journal of Pharmacology and Therapy

Current pharmacological treatments for COVID-19: A narrative review Sudi Indra Jaya; Yacobus Christian Prasetyo
Indonesian Journal of Pharmacology and Therapy Vol 2 No 3 (2021): Special Issue: COVID-19
Publisher : Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada and Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFARI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/ijpther.2881

Abstract

The coronavirus disease 2019 (COVID-19) pandemic has lasted more than one year. The number of daily cases and the number of deaths is still changing dynamically. As of this writing, specific drugs for COVID-19 are not yet available. This review aims to describe the key clinical evidence in pharmacological treatments for COVID-19. The article search process was carried out on the PubMed database with a combination of keywords ((“COVID-19”) OR (“SARS-CoV-2”)) AND ((“treatment”) OR (“therapy”)). In this article, there were six drugs reviewed that is corticosteroids, remdesivir, lopinavir-ritonavir, hydroxychloroquine, ivermectin, and interleukin-6 (IL-6) receptor blockers. Hydroxychloroquine, lopinavir-ritonavir, remdesivir, and ivermectin were not recommended for COVID-19 treatments regardless of disease severity and duration of symptoms. Therefore, they were excluded from the list of drugs for the treatment of COVID-19 by World Health Organization (WHO) stated strong recommendations in favor of two drugs, namely systemic corticosteroids and IL-6 receptor blockers namely tocilizumab or sarilumab. Both of them are recommended for the treatment of patients with severe and critical covid-19 so they are included in the list of COVID-19 therapeutic drugs by WHO.
Tamarindus indica increases the stability of jamu kunyit-asam herbal suspension over Citrus aurantifolia wicaksono, arko jatmiko; Rakhmawati, rita; Wahyuningsih, Mae Sri Hartati; Syarif, Rul Afiyah; Prasetyo, Yacobus Christian
Indonesian Journal of Pharmacology and Therapy Vol 5 No 2 (2024)
Publisher : Faculty of Medicine, Public Health, and Nursing Universitas Gadjah Mada and Indonesian Pharmacologist Association or Ikatan Farmakologi Indonesia (IKAFARI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22146/ijpther.11818

Abstract

Rapid shelf-life of traditional supplementary drink still becomes major issue for herbal production in household industries. In this study the stability formula of an herbal suspension, so called as jamu kunyit-asam, was investigated. The jamu kunyit-asam Formula-1 (F1) contains combination of Citrus aurantifolia and Curcuma longa. While the Formula-2 (F2) is consisted by mixture of Tamarindus indica and C. longa. The two formulas were compared to justify better stability between preparations. No preservatives were added, in order to comply with the local regulation. To simulate the real situation, all samples were stored in 4 different conditions: opened bottle (room temperature), closed bottle (room temperature), closed bottle (refrigerator), and freeze-thaw condition. To evaluate the stability profile, an organoleptic testing and pH alteration were frequently checked for 12 consecutive days. Several parameters including color changing, sting odor, and microscopic appearance were looked over. As the results, mold, precipitation and pungent odor were formed faster from the F1 (C. aurantifolia combined with C. longa). These findings indicates that jamu kunyit-asam herbal drink suspensions containing C. longa has less stability in combination with the C. aurantifolia (F1) compared to the T. indica (F2).